Patents Assigned to Genmab A/S
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE
    Publication number: 20180022816
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: June 20, 2017
    Publication date: January 25, 2018
    Applicant: GENMAB A/S
    Inventors: Bart DE GOEIJ, Edward N. VAN DEN BRINK, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, D.M.Sc., David SATIJN, Jan VAN DE WINKEL, Paul PARREN
  • Monoclonal antibodies against HER2
    Patent number: 9862769
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 9, 2018
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • RODENT BISPECIFIC HETERODIMERIC PROTEINS
    Publication number: 20170327597
    Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 16, 2017
    Applicant: GENMAB A/S
    Inventors: Aran F. LABRIJN, Joyce I. MEESTERS, Janine SCHUURMAN, Paul PARREN, Anthony ARMSTRONG, Matthew BUNCE, Mark CHIU, Thomas NESSPOR, Adam ZWOLAK
  • Monoclonal antibodies against HER2 epitope
    Patent number: 9714294
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: July 25, 2017
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Edward Norbert Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
  • Human antibodies against tissue factor and methods of use thereof
    Patent number: 9714297
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 25, 2017
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, David P. E. Satijn, Rene M. A. Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N. De Jong
  • Monoclonal antibodies against CD32b
    Patent number: 9663578
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 30, 2017
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Paul Parren, Jan Van De Winkel, Aran Frank Labrijn, Frank Everhardus Martinus Rebers, Esther Cornelia Wilhelmina Breij
  • Monoclonal antibodies against c-Met
    Patent number: 9657107
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: May 23, 2017
    Assignee: GENMAB A/S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Human monoclonal antibodies against CD25
    Patent number: 9598493
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: March 21, 2017
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • Potency assays for antibody drug substance binding to an Fc receptor
    Patent number: 9580506
    Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: February 28, 2017
    Assignee: GENMAB A/S
    Inventors: Catharina Emanuele Gerarda Havenith, Tom Vink, Patrick Van Berkel, Paul Parren
  • STABLE IgG4 ANTIBODIES
    Publication number: 20170029521
    Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Application
    Filed: June 29, 2016
    Publication date: February 2, 2017
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Tom VINK, Janine SCHUURMAN, Paul PARREN, Rob AALBERSE, Marijn VAN DER NEUT KOLFSCHOTEN
  • Methods and antibodies for treating cancer
    Patent number: 9540450
    Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: January 10, 2017
    Assignee: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Willem Karel Bleeker, Klaus Edvardsen, Jeroen Lammerts Van Bueren, Thomas Valerius, Michael Dechant, Wencke Weisner, Sven Berger
  • Human antibodies and antibody-drug conjugates against CD74
    Patent number: 9540433
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: January 10, 2017
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20160333095
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Applicant: GENMAB A/S
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Isil ALTINTAS, Paul PARREN, Rik RADEMAKER
  • Human antibody drug conjugates against tissue factor
    Patent number: 9492565
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: November 15, 2016
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
    Patent number: 9458236
    Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: October 4, 2016
    Assignee: GENMAB A/S
    Inventors: Jan G. J. Van De Winkel, Marcus Antonius Van Dijk, Edward Halk, Arnout F. Gerritsen, Jørgen Petersen, Ole Baadsgaard
  • Method of treating rash in patients undergoing anti-EGFR therapy
    Patent number: 9428582
    Abstract: The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 30, 2016
    Assignee: GENMAB A/S
    Inventors: Klaus Edvardsen, Steen Lisby, Ole Baadsgaard
  • Recombinant IgG4 monovalent antibodies
    Patent number: 9322035
    Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: April 26, 2016
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Frank Beurskens, Patrick Van Berkel
  • Therapy with CD4 binding peptides and radiation
    Patent number: 9309315
    Abstract: The present invention relates to a peptide, such as an antibody, capable of binding to CD4 and use thereof for the mediation of radiation treatment of a clinical condition. The radiation treatment may for instance by treatment with PUVA.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: April 12, 2016
    Assignee: GENMAB A/S
    Inventors: Paul Parren, Ole Baadsgaard, Denis Alexander
  • Antibodies against human CD38
    Patent number: 9249226
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: February 2, 2016
    Assignee: GENMAB A/S
    Inventors: Michel de Weers, Tim Walseth, Jan van de Winkel, Tom Vink, Paul Parren
  • Bispecific antibodies and methods for production thereof
    Patent number: 9212230
    Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 15, 2015
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Rob Aalberse, Marijn Van Der Neut Kolfschote, Paul Parren